Assessing MBX Biosciences (MBX) Valuation After CEO Share Purchase And Phase 3 Hypoparathyroidism Plans

MBX Biosciences (MBX) is back on investor radars after CEO P. Kent Hawryluk reported buying 18,500 additional shares as the company prepares its lead hypoparathyroidism therapy for a Phase 3 trial.

See our latest analysis for MBX Biosciences.

At a latest share price of $28.50, MBX has seen a 1 year total shareholder return of about 2.7x, while its 30 day share price return of 12.4% and year to date share price return of 6.7% suggest some recent cooling in momentum after a strong run into upcoming clinical milestones and the CEO’s recent purchase.

If you are looking beyond MBX for other growth stories in healthcare and biotech, this is a good moment to scan for precision medicine peers and discover 34 healthcare AI stocks

With MBX shares up about 2.7x over the past year and recent returns easing off, the key question now is whether current levels still leave room for upside or if the market is already pricing in future growth.

Preferred Price-to-Book Multiple of 3.7x: Is it justified?

MBX currently trades on a P/B of 3.7x, which sits between peer averages and the broader US Pharmaceuticals industry and gives you a mixed valuation signal at the latest close of $28.50.

The P/B ratio compares a company’s market value to its net assets on the balance sheet. This can be a useful lens for a clinical stage biotech where earnings are still negative and revenue is yet to scale. For MBX, this multiple is being applied to a business with no meaningful revenue, a reported net loss of $86.971m, and forecasts that point to ongoing losses over the next three years.

Relative to a specific peer set, MBX screens as good value, with its 3.7x P/B sitting well below a peer average of 8.2x. Against the broader US Pharmaceuticals industry, that same 3.7x looks expensive compared with an industry average of 2x. This suggests the market is assigning MBX a richer balance sheet premium than many other listed drug developers.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 3.7x (ABOUT RIGHT)

However, you still need to weigh clinical and regulatory risk around Canvuparatide’s Phase 3 path, as well as the ongoing net loss of $86.971m, against today’s valuation.

Find out about the key risks to this MBX Biosciences narrative.

Next Steps

Feeling cautious or optimistic after looking at MBX so far? Take a closer look at the underlying data now and weigh the 5 important warning signs.

Looking for more investment ideas?

If MBX has caught your attention, do not stop here. Broaden your watchlist now with fresh ideas that line up with your risk comfort and return goals.

• Spot potential bargains early by checking out screener containing 25 high quality undiscovered gems before they move onto everyone else's radar.
• Prioritise resilience by scanning 64 resilient stocks with low risk scores that may offer a smoother ride when markets get choppy.
• Focus on financial strength with the solid balance sheet and fundamentals stocks screener (39 results) to see companies combining sturdy balance sheets with fundamental support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com